Lv1
46 积分 2022-01-07 加入
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
6天前
已完结
Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for α‐fetoprotein‐producing gastric carcinoma
2个月前
已完结
1493P Stratifying late progression risk beyond two years of immunotherapy using methylation-based ctDNA analysis in advanced HCC
2个月前
已完结
Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments
2个月前
已完结
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
3个月前
已完结
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
3个月前
已完结
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
3个月前
已完结
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
3个月前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
